The city of Doha, a vibrant hub of innovation in the Gulf, will host the next major international event for Genenta Science (Nasdaq: GNTA), an Italo-American company specializing in cell-based therapies and a leader in immuno-oncology. CEO Pierluigi Paracchi will speak on April 17, 2025, at the Qatar stop of the Montalcini Global Biotech Tour, held at the Sheikh Fahad bin Jassim Al Thani Theatre, Ministry of Commerce and Industry.
The event, hosted by Ahmed bin Mohammed Al Sayed, Minister of State for Foreign Trade Affairs of Qatar, and Italian Minister of Health Orazio Schillaci, serves as a strategic platform for dialogue between global biotech ecosystems. Opening remarks will be delivered by Paolo Toschi, Ambassador of Italy to Qatar.
A Key Moment for Genenta’s Expansion
Genenta’s participation in the forum comes at a pivotal time, following the announcement of a significant financing operation: a €20 million Mandatory Convertible Bond subscribed by ENEA Tech and Biomedical (ETB), along with an additional €3 million raised through an at-the-market (ATM) facility. These funds will support the expansion of Genenta’s pipeline, particularly the development of Temferon™ for metastatic renal cell carcinoma (mRCC).
Temferon™ is the company’s proprietary platform and the cornerstone of its innovation. It is an investigational therapy based on genetically engineered hematopoietic stem cells, designed to act directly within the tumor microenvironment via bone marrow-derived myeloid cells, aiming to overcome immune tolerance and trigger a targeted and durable T cell response. After completing Phase 1 in newly diagnosed glioblastoma multiforme (GBM) patients with unmethylated MGMT promoter, Genenta launched a Phase 1/2a trial for metastatic RCC in Q4 2024, which also includes combination therapy with immune checkpoint inhibitors.
About Genenta
Genenta is a clinical-stage biotech company based in Milan and New York, founded on the concept of using bone marrow-derived cells as smart delivery systems for immune payloads within tumors. Its therapies are designed as one-time monotherapies, with additional potential to boost the effectiveness of other approved treatments when used in combination.
With its innovative approach and strong institutional investor network, Genenta stands out as one of the most promising biotech firms in Europe — now poised to play a key role in the Middle East as well.
Italian Biotech on the Global Stage
As part of the Montalcini Global Biotech Tour, Paracchi will also speak in his capacity as Moderator of the National Working Table for the Internationalization of Italian Biotech (NWTIB), an initiative promoted by Italian Deputy Prime Minister and Minister of Foreign Affairs Antonio Tajani. The session titled “Italian Biotech & Lifesciences Ecosystem” will also feature Massimo Carnelos, Head of the Office for Technological Innovation and Startups at the Italian Ministry of Foreign Affairs, and Mario Scuderi, Senior Partner at CDP Venture Capital, a long-standing investor in Genenta and participant in its 2021 Nasdaq IPO.
The program will also include presentations from the Qatar Research, Development and Innovation Council (QRDI), represented by Dr. Sara A. Abdulla, and will conclude with bilateral meetings with representatives of the Qatar Investment Authority (QIA), the country’s sovereign wealth fund managing over $475 billion in assets — a key strategic partner in international collaborations.
A Bridge Between Milan, New York, and Doha
Genenta’s invitation marks international recognition of the Milan-based biotech’s pioneering role in the field of immuno-oncologic therapies. Qatar’s interest in cutting-edge regenerative and personalized medicine creates fertile ground for future institutional and industrial partnerships.